Needham & Company Maintains a 'Buy' on Dyax Corp. (DYAX); Strong Kalbitor Growth Trends
Tweet Send to a FriendGet Alerts DYAX Hot Sheet
Price: $3.23 --0%
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Rating Summary:
3 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 21
Trade DYAX Now!
Needham & Company maintains a 'Buy' on Dyax Corp. (NASDAQ: DYAX) price target of $3.50.
Analyst, Serge Belanger, said, "DYAX reported another quarter of impressive Kalbitor growth. Management continues to show solid commercial execution with a comprehensive set of patient support and services programs (i.e., home infusion service) driving patient enrollment and treatment rates. Kalbitor is also benefitting from updated HAE treatment guidelines that emphasize the use of on-demand treatments. DYAX stock has had an impressive performance over the last Q, benefitting from stable Kalbitor growth and investors’ increased appetite for small-cap biotech."
Raises FY12/13 EPS estimate by $0.01 to (0.35) and (0.16), respectively.
For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.
Shares of Dyax Corp. closed at $2.72 yesterday, with a 52 week range of $1.10-$2.83.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Serge Belanger, said, "DYAX reported another quarter of impressive Kalbitor growth. Management continues to show solid commercial execution with a comprehensive set of patient support and services programs (i.e., home infusion service) driving patient enrollment and treatment rates. Kalbitor is also benefitting from updated HAE treatment guidelines that emphasize the use of on-demand treatments. DYAX stock has had an impressive performance over the last Q, benefitting from stable Kalbitor growth and investors’ increased appetite for small-cap biotech."
Raises FY12/13 EPS estimate by $0.01 to (0.35) and (0.16), respectively.
For an analyst ratings summary and ratings history on Dyax Corp. click here. For more ratings news on Dyax Corp. click here.
Shares of Dyax Corp. closed at $2.72 yesterday, with a 52 week range of $1.10-$2.83.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- UPDATE: UBS Starts Insmed (INSM) at Buy
- UPDATE: Canaccord Genuity Starts T-Mobile US, (TMUS) at Hold
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
